Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Chief Scientific Officer | March 11, 2025 | March 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date March 11, 2025 · Filed March 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 195,840 |
Reported balance
After 2025-03-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-11 · Sale · Disposed 2,153 · Balance 195,840 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.25 to $11.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3: Includes 152,839 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.25 to $11.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F3: Includes 152,839 unvested RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2025 Filed Mar 13, 2025 16:08 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,153 | $11.38 | $24,501.14 |
DisclosureSEC source: 0000950170-25-038726 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,840 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.25 to $11.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 152,839 unvested RSUs. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,094 | $11.83 | $12,942.02 |
DisclosureSEC source: 0000950170-25-035472 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,993 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.73 to $11.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 157,622 unvested RSUs. Read SEC document |
| February 18, 2025 Filed Feb 25, 2025 17:09 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,598 | $13.95 | $36,242.10 |
DisclosureSEC source: 0000950170-25-026837 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,087 F1 · date: This transaction is being reported late due to an inadvertent administrative error. F2 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.95 to $14.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F4 · balance_after: Includes 160,065 unvested RSUs. Read SEC document |
| December 11, 2024 Filed Dec 11, 2024 20:41 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,334 | $28.12 | $65,632.08 |
DisclosureSEC source: 0000950170-24-135571 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,685 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.76 to $28.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 165,922 unvested RSUs. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 16:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 62,400 | $0.00 Strike: $29.44 | $0.00 |
DisclosureSEC source: 0000950170-24-134070 · ownership.xml · derivative · entry 3 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,400 Underlying: Common Stock · 62,400 shares Expires 2034-12-03 F4 · derivative.exercise_date: This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 16:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 27,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-134070 · ownership.xml · nonDerivative · entry 2 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,019 F2 · shares: Consists of shares of Common Stock issuable under 27,400 RSUs. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in full on December 4, 2025. F3 · balance_after: Includes 170,705 unvested RSUs. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 16:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 39,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-134070 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,619 F1 · shares: Consists of shares of Common Stock issuable under 39,100 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025. Read SEC document |
| November 18, 2024 Filed Nov 18, 2024 16:28 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,856 | $28.20 | $80,539.20 |
DisclosureSEC source: 0000950170-24-127989 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,519 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.00 to $28.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 104,205 unvested RSUs. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 16:51 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,339 | $34.55 | $80,812.45 |
DisclosureSEC source: 0000950170-24-108151 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,375 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.35 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 110,062 unvested RSUs. Read SEC document |
| September 11, 2024 Filed Sep 11, 2024 16:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,161 | $31.89 | $68,914.29 |
DisclosureSEC source: 0000950170-24-105517 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,714 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.59 to $32.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 114,885 unvested RSUs. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 16:26 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 296 | $46.00 | $13,616.00 |
DisclosureSEC source: 0000950170-24-099122 · ownership.xml · nonDerivative · entry 2 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,875 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive. F4 · balance_after: Includes 119,668 unvested RSUs. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 16:26 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,340 | $45.01 | $105,323.40 |
DisclosureSEC source: 0000950170-24-099122 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,171 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 19:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,136 | $31.34 | $66,942.24 |
DisclosureSEC source: 0000950170-24-072170 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,511 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 125,525 unvested RSUs. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:01 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 30,426 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-063737 · ownership.xml · derivative · entry 5 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,426 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on January 27, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:01 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,145 | $34.08 | $39,021.60 |
DisclosureSEC source: 0000950170-24-063737 · ownership.xml · nonDerivative · entry 4 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,647 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.02 to $34.16, inclusive. F5 · balance_after: Includes 130,308 unvested RSUs. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:01 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 12,147 | $33.51 | $407,045.97 |
DisclosureSEC source: 0000950170-24-063737 · ownership.xml · nonDerivative · entry 3 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $33.01 to $34.01, inclusive. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:01 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 17,134 | $32.49 | $556,683.66 |
DisclosureSEC source: 0000950170-24-063737 · ownership.xml · nonDerivative · entry 2 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,939 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $32.00 to $33.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:01 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 30,426 | $1.03 | $31,338.78 |
DisclosureSEC source: 0000950170-24-063737 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2024 Filed May 17, 2024 21:07 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 483 | $28.59 | $13,808.97 |
DisclosureSEC source: 0000950170-24-062080 · ownership.xml · nonDerivative · entry 2 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,647 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.51 to $28.70, inclusive. F4 · balance_after: Includes 130,308 unvested RSUs. Read SEC document |
| May 16, 2024 Filed May 17, 2024 21:07 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,222 | $28.20 | $62,660.40 |
DisclosureSEC source: 0000950170-24-062080 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,130 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 21:42 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,081 | $25.70 | $53,481.70 |
DisclosureSEC source: 0000950170-24-030443 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,352 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 136,165 unvested RSUs. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,373 | $25.85 | $61,342.05 |
DisclosureSEC source: 0000950170-24-029615 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,433 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.84 to $26.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 140,948 unvested RSUs. Read SEC document |
| January 04, 2024 Filed Jan 4, 2024 21:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 42,453 | $18.13 | $769,672.89 |
DisclosureSEC source: 0000950170-24-002279 · ownership.xml · nonDerivative · entry 6 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,806 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.45, inclusive. F1 · balance_after: Includes 146,805 unvested RSUs. Read SEC document |
| January 04, 2024 Filed Jan 4, 2024 21:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 22,674 | $1.03 | $23,354.22 |
DisclosureSEC source: 0000950170-24-002279 · ownership.xml · nonDerivative · entry 5 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 146,805 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 45,326 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-002279 · ownership.xml · derivative · entry 7 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,100 Underlying: Common Stock · 45,326 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on January 27, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 5,361 | $20.50 | $109,900.50 |
DisclosureSEC source: 0000950170-24-002279 · ownership.xml · nonDerivative · entry 4 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,585 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.50 to $20.56, inclusive. F1 · balance_after: Includes 146,805 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 24,583 | $19.05 | $468,306.15 |
DisclosureSEC source: 0000950170-24-002279 · ownership.xml · nonDerivative · entry 3 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,946 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive. F1 · balance_after: Includes 146,805 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 15,382 | $18.34 | $282,105.88 |
DisclosureSEC source: 0000950170-24-002279 · ownership.xml · nonDerivative · entry 2 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,529 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. F1 · balance_after: Includes 146,805 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 45,326 | $1.03 | $46,685.78 |
DisclosureSEC source: 0000950170-24-002279 · ownership.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 146,805 unvested RSUs. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 17:32 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,467 | $10.72 | $15,726.24 |
DisclosureSEC source: 0001209191-23-058326 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,585 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.72 to $10.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 146,805 unvested RSUs. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 16:23 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 36,495 | $0.00 Strike: $10.88 | $0.00 |
DisclosureSEC source: 0001209191-23-055521 · doc4.xml · derivative · entry 2 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,495 Underlying: Common Stock · 36,495 shares Expires 2033-11-14 F3 · derivative.exercise_date: This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 16:23 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 93,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055521 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,052 F1 · shares: Consists of shares of Common Stock issuable under 93,718 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024. F2 · balance_after: Includes 151,588 unvested RSUs. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 16:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,436 | $9.41 | $13,512.76 |
DisclosureSEC source: 0001209191-23-050168 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,334 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 57,870 unvested RSUs. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 19:50 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,484 | $10.41 | $15,448.44 |
DisclosureSEC source: 0001209191-23-049356 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,770 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.08 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 62,692 unvested RSUs. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 18:39 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,475 | $12.43 | $18,334.25 |
DisclosureSEC source: 0001209191-23-037163 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,254 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 67,475 unvested RSUs. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 17:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,416 | $13.33 | $18,875.28 |
DisclosureSEC source: 0001209191-23-018977 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,729 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 72,258 unvested RSUs. Read SEC document |
| January 04, 2023 Filed Jan 4, 2024 21:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 22,674 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-002279 · ownership.xml · derivative · entry 8 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,426 Underlying: Common Stock · 22,674 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on January 27, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 17:03 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 680 | $10.87 | $7,391.60 |
DisclosureSEC source: 0001209191-22-060964 · doc4.xml · nonDerivative · entry 2 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,145 F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4 · balance_after: Includes 77,041 unvested RSUs. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 17:03 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 63,000 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001209191-22-060964 · doc4.xml · derivative · entry 3 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2032-12-08 F5 · derivative.exercise_date: This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 17:03 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060964 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,825 F1 · shares: Consists of shares of Common Stock issuable under 40,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023. F2 · balance_after: Includes 79,323 unvested RSUs. Read SEC document |
| September 20, 2022 Filed Sep 21, 2022 16:07 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Disposition to issuerCommon Stock | 1,413 | $13.70 | $19,358.10 |
DisclosureSEC source: 0001209191-22-050881 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,825 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $13.70 to $13.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F3 · balance_after: Includes 39,323 unvested RSUs. Read SEC document |
| September 15, 2022 Filed Sep 15, 2022 17:24 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Disposition to issuerCommon Stock | 712 | $14.05 | $10,003.60 |
DisclosureSEC source: 0001209191-22-050117 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,238 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F3 · balance_after: Includes 44,145 unvested RSUs. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 18:17 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 23,477 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0001209191-22-041328 · doc4.xml · derivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,477 Underlying: Common Stock · 23,477 shares Expires 2030-07-30 F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 20:02 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Disposition to issuerCommon Stock | 726 | $4.95 | $3,593.70 |
DisclosureSEC source: 0001209191-22-037142 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,950 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 46,427 unvested RSUs. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 17:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 693 | $8.73 | $6,049.89 |
DisclosureSEC source: 0001209191-22-018530 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,676 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.65 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F3 · balance_after: Includes 48,709 unvested RSUs. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 16:19 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 54,786 | $0.00 Strike: $13.12 | $0.00 |
DisclosureSEC source: 0001209191-21-069418 · doc4.xml · derivative · entry 2 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,786 Underlying: Common Stock · 54,786 shares Expires 2031-12-09 F3 · derivative.exercise_date: This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 16:19 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 36,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069418 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,369 F1 · shares: Consists of shares of Common Stock issuable under 36,524 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022. F2 · balance_after: Includes 50,991 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:01 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 827 | $16.11 | $13,322.97 |
DisclosureSEC source: 0001209191-21-057323 · doc4.xml · nonDerivative · entry 2 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,845 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 21, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.87 to $16.36, inclusive. F3 · balance_after: Includes 14,467 unvested RSUs. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 20:01 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 617 | $15.61 | $9,631.37 |
DisclosureSEC source: 0001209191-21-057323 · doc4.xml · nonDerivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,672 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.22 to $16.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in footnote (2) and (4) of this Form 4. F3 · balance_after: Includes 14,467 unvested RSUs. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 18:41 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $19.05 | $0.00 |
DisclosureSEC source: 0000899243-21-021642 · doc4.xml · derivative · entry 1 Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: This option was granted on June 2, 2021. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on June 2, 2022 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.